Cargando…

The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour

Background Glucagon-like peptide-1 receptor agonists (GLP-1 RA) added to insulin in type 2 diabetes patients have shown to lower body weight, improve glycaemic control and reduce total daily insulin dose in short term studies, although the individual response greatly varies. Objective To evaluate GL...

Descripción completa

Detalles Bibliográficos
Autores principales: de Boer, Stefanie Amarens, Lefrandt, Joop Daniel, Petersen, Japke Frida, Boersma, Hendrikus Hessel, Mulder, Douwe Johannes, Hoogenberg, Klaas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733138/
https://www.ncbi.nlm.nih.gov/pubmed/26597956
http://dx.doi.org/10.1007/s11096-015-0219-8
_version_ 1782412799280939008
author de Boer, Stefanie Amarens
Lefrandt, Joop Daniel
Petersen, Japke Frida
Boersma, Hendrikus Hessel
Mulder, Douwe Johannes
Hoogenberg, Klaas
author_facet de Boer, Stefanie Amarens
Lefrandt, Joop Daniel
Petersen, Japke Frida
Boersma, Hendrikus Hessel
Mulder, Douwe Johannes
Hoogenberg, Klaas
author_sort de Boer, Stefanie Amarens
collection PubMed
description Background Glucagon-like peptide-1 receptor agonists (GLP-1 RA) added to insulin in type 2 diabetes patients have shown to lower body weight, improve glycaemic control and reduce total daily insulin dose in short term studies, although the individual response greatly varies. Objective To evaluate GLP-1 RA treatment on body weight, glycaemic control and total daily insulin dose in obese, insulin-using type 2 diabetes patients after 2 years follow-up in a real life setting and to explore a possible relation with eating behaviour. Setting The Martini Hospital and the University Medical Center in Groningen in the Netherlands. Methods Eligible patients were at least 18 years of age, were on insulin therapy and obese (BMI > 30 kg/m(2)), started GLP-1 RA treatment. At baseline eating behaviour was classified according to the validated Dutch Eating Behaviour Questionnaire. A 2 years follow-up was performed. Main outcome measures Body weight, HbA1c and total daily insulin dose. Results 151 Patients started with exenatide or liraglutide. 120 patients completed the 2 years follow-up. From baseline to 2 years, body weight (mean ± SD) changed from 117.9 ± 22.1 to 107.9 ± 22.9 kg (P < 0.0001), HbA1c (median, IQR) changed from 7.9 (7.2–8.9) to 7.6 (6.9–8.3) % [63 (55–74) to 60 (52–67) mmol/mol] (P < 0.0001), total daily insulin dose changed from 90 (56–150) to 60 (0–100) Units/day (P < 0.0001). Weight change differed between eating behaviour groups (P < 0.001) in which external eating behaviour (n = 17) resulted in the smallest decline (−3.1 %) and restrained (n = 41) in the greatest (−10.3 %) in comparison with emotional (n = 37, −8.5 %) and indifferent (n = 25, −9.6 %) eating behaviours. Conclusion Two year of GLP-1 RA treatment resulted in a sustained reduction of weight, HbA1c and total daily insulin dose in obese, insulin-using type 2 diabetes patients in a real life setting. Largest weight loss was achieved in patients with a predominant restraint eating pattern while a predominant external eating pattern resulted in the smallest weight reduction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11096-015-0219-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4733138
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-47331382016-02-05 The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour de Boer, Stefanie Amarens Lefrandt, Joop Daniel Petersen, Japke Frida Boersma, Hendrikus Hessel Mulder, Douwe Johannes Hoogenberg, Klaas Int J Clin Pharm Research Article Background Glucagon-like peptide-1 receptor agonists (GLP-1 RA) added to insulin in type 2 diabetes patients have shown to lower body weight, improve glycaemic control and reduce total daily insulin dose in short term studies, although the individual response greatly varies. Objective To evaluate GLP-1 RA treatment on body weight, glycaemic control and total daily insulin dose in obese, insulin-using type 2 diabetes patients after 2 years follow-up in a real life setting and to explore a possible relation with eating behaviour. Setting The Martini Hospital and the University Medical Center in Groningen in the Netherlands. Methods Eligible patients were at least 18 years of age, were on insulin therapy and obese (BMI > 30 kg/m(2)), started GLP-1 RA treatment. At baseline eating behaviour was classified according to the validated Dutch Eating Behaviour Questionnaire. A 2 years follow-up was performed. Main outcome measures Body weight, HbA1c and total daily insulin dose. Results 151 Patients started with exenatide or liraglutide. 120 patients completed the 2 years follow-up. From baseline to 2 years, body weight (mean ± SD) changed from 117.9 ± 22.1 to 107.9 ± 22.9 kg (P < 0.0001), HbA1c (median, IQR) changed from 7.9 (7.2–8.9) to 7.6 (6.9–8.3) % [63 (55–74) to 60 (52–67) mmol/mol] (P < 0.0001), total daily insulin dose changed from 90 (56–150) to 60 (0–100) Units/day (P < 0.0001). Weight change differed between eating behaviour groups (P < 0.001) in which external eating behaviour (n = 17) resulted in the smallest decline (−3.1 %) and restrained (n = 41) in the greatest (−10.3 %) in comparison with emotional (n = 37, −8.5 %) and indifferent (n = 25, −9.6 %) eating behaviours. Conclusion Two year of GLP-1 RA treatment resulted in a sustained reduction of weight, HbA1c and total daily insulin dose in obese, insulin-using type 2 diabetes patients in a real life setting. Largest weight loss was achieved in patients with a predominant restraint eating pattern while a predominant external eating pattern resulted in the smallest weight reduction. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11096-015-0219-8) contains supplementary material, which is available to authorized users. Springer International Publishing 2015-11-23 2016 /pmc/articles/PMC4733138/ /pubmed/26597956 http://dx.doi.org/10.1007/s11096-015-0219-8 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research Article
de Boer, Stefanie Amarens
Lefrandt, Joop Daniel
Petersen, Japke Frida
Boersma, Hendrikus Hessel
Mulder, Douwe Johannes
Hoogenberg, Klaas
The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
title The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
title_full The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
title_fullStr The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
title_full_unstemmed The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
title_short The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
title_sort effects of glp-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733138/
https://www.ncbi.nlm.nih.gov/pubmed/26597956
http://dx.doi.org/10.1007/s11096-015-0219-8
work_keys_str_mv AT deboerstefanieamarens theeffectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour
AT lefrandtjoopdaniel theeffectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour
AT petersenjapkefrida theeffectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour
AT boersmahendrikushessel theeffectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour
AT mulderdouwejohannes theeffectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour
AT hoogenbergklaas theeffectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour
AT deboerstefanieamarens effectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour
AT lefrandtjoopdaniel effectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour
AT petersenjapkefrida effectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour
AT boersmahendrikushessel effectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour
AT mulderdouwejohannes effectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour
AT hoogenbergklaas effectsofglp1analoguesinobeseinsulinusingtype2diabetesinrelationtoeatingbehaviour